This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Taiho Pharmaceutical Company Limited. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Hirokazu Fuchida: Innovator in EGFR Inhibition
Introduction
Hirokazu Fuchida is a prominent inventor based in Ibaraki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit the epidermal growth factor receptor (EGFR). His work is crucial in the ongoing fight against various cancers.
Latest Patents
Hirokazu Fuchida holds a patent for "Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors." This invention provides a novel compound that inhibits EGFR or a salt of the compound. According to one embodiment of the invention, a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is provided. This innovation has the potential to impact cancer treatment significantly.
Career Highlights
Fuchida is associated with Taiho Pharmaceutical Company Limited, where he has been instrumental in advancing research and development in oncology. His expertise in medicinal chemistry has led to breakthroughs that enhance therapeutic options for patients.
Collaborations
Hirokazu Fuchida has collaborated with notable colleagues, including Fuyuki Yamamoto and Takashi Mizutani. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Hirokazu Fuchida's contributions to the field of EGFR inhibition exemplify the importance of innovation in medicine. His work continues to pave the way for new treatments that can improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile